Completed PHASE4 INTERVENTIONAL 2-arm NCT02416271

The Forteo Alendronate Comparator Trial (FACT)

Teriparatide Compared With Alendronate on Spine Bone Mineral Density in Postmenopausal Women With Osteoporosis

Sponsor: Eli Lilly and Company

Interventions Alendronate Calcium Placebo-Oral Placebo-SC Teriparatide Vitamin D

Updated 6 times since 2017 Last updated: Apr 9, 2015 Started: Apr 30, 2001 Primary completion: May 31, 2003 Completion: May 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02416271, this PHASE4 trial focuses on Osteoporosis and remains completed. Sponsored by Eli Lilly and Company, it has been updated 6 times since 2001, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Feb 2017 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Apr 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arden Hills, United States , Chicago, United States , Greenville, United States , Honolulu, United States , Indianapolis, United States , Lakewood, United States , Mexico City, Mexico , Mezzanine, Mexico , Mobile, United States , Morristown, United States and 10 more locations